Children treated with anti-TNF therapy at risk for weight gain, obesity Source: Disclosures: Mitchel reports no relevant financial relationships. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Back to Healio
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Back to Healio
Children with inflammatory bowel disease who receive anti-tumor necrosis factor treatment were more likely to see BMI levels increase and incur a risk for obesity, according to a presentation at Crohn’s and Colitis Congress.
This article is a collaboration between MedPage Today and:
Both the Mediterranean diet and the Specific Carbohydrate diet were effective for symptom reduction in patients with Crohn s disease, a randomized clinical trial demonstrated.
At week 6, symptomatic remission was achieved by 44% of patients on the Mediterranean diet and by 47% of those following the Specific Carbohydrate diet, reported James D. Lewis, MD, of the University of Pennsylvania in Philadelphia at the virtual Crohn s and Colitis Congress.
And clinical remission defined by the Crohn s Disease Activity Index also was observed in similar numbers, at 48% for the Mediterranean diet and 49% for the Specific Carbohydrate diet.
Biologic use before surgery not linked with increased infections Source:
Holubar SD, et al. Adult IBD: Quick Shots Abstracts and Case Discussions. Presented at: Crohn’s and Colitis Congress. Jan. 21-24, 2020. Disclosures: Holubar reports no relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Back to Healio
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
This article is a collaboration between MedPage Today and:
Among older adults with inflammatory bowel disease (IBD), vedolizumab (Entyvio) appeared to be safer than tumor necrosis factor (TNF) inhibitors, a large retrospective study suggested.
After weighting using standardized mean differences, new users of vedolizumab had a lower likelihood of all-cause hospitalization during the 12 months after initiating biologic treatment compared with those starting TNF inhibitors, with a hazard ratio of 0.81 (95% CI 0.68-0.96), according to Bharati Kochar, MD, of Massachusetts General Hospital in Boston.
In addition, while there was no difference between vedolizumab and anti-TNF initiators in IBD-related hospitalizations, those on vedolizumab had a lower risk of infection-related hospitalization, with a hazard ratio of 0.39 (95% CI 0.23-0.65), she reported at the virtual Crohn s and Colitis Congress.